Chloe Orkin on long-acting cabotegravir

The Lancet HIV in conversation with - A podcast by The Lancet Group

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Education

Professor Chloe Orkin (Queen Mary University London, UK) joins Peter Hayward to talk about long-acting cabotegravir for HIV treatment and the 96 weeks of the FLAIR study. Read the full article: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30340-4/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https...